Figure 2.

CreERT model labels healthy adult Gli1-expressing fibroblasts. (A) Genetic scheme for Gli1^CreERT/+ crossed with either a Rosa26^YFP/+ or a Rosa26^tdTomato/+ reporter. (B) Experimental design for examining healthy adult mice expressing Gli1 in the pancreas. Adult mice ages 5–8 weeks were given tamoxifen gavages (4 mg/mouse/day) for 5 days. Tissue was examined 1 week after completing gavages. (C) IHC staining for YFP in healthy adult mice. Scale bar: 50 um. (D) IF staining of the following: Lyve-1 (green), Tomato (red), and DAPI (blue); NG2 (green), Tomato (red), and DAPI (blue); PDGFRβ (green), Tomato (red), and DAPI (blue); and αSMA (green), Tomato (red), and DAPI (blue) in Gli1^CreERT/+;RTom samples. Scale bar: 50 um. (E) Genetic scheme for a Gli1^CreER/+;Gli1^EGFP/+,RTomato mouse model. (F) IF staining of GFP and Tomato in the Gli1^CreERT/+;Gli1^EGFP/+;RTom mouse. Scale bar: 50 um. (G) Representative YFP vs PDGFR⍺, flow cytometry plots of DAPI^- cells in a healthy Gli1^CreERT/+;RYFP mouse and wild-type control and the quantification (n ≥ 10). (H) Representative YFP vs CD45 flow cytometry plot. (I) Quantification of the percentage of YFP⁺ cells that expressed CD45, PDGFR⍺, or CD105, as determined by flow cytometry gating. All data are expressed as means ± SEM. TAM, tamoxifen; TOM, Tomato; WT, wild-type.